Authors


Cardinal

Latest:

Preparing for the Growth of Cold Chain

Cardinal Health helps create a more predictable and efficient supply chain by investing in the future of cold-chain storage and transportation.


Gwen Volpe, RPh

Latest:

The Promise of RFID for Improving Medication Inventory Management

Radio frequency identification (RFID) not only helps hospitals boost their medication safety standards, it also allows clinicians to continue to provide quality patient care.


Chris Leggett

Latest:

The Future State of Oncology: The Rise of Oncology Home Care

While there are still hurdles to overcome along the way, home healthcare could deliver better patient-centered cancer care, providing improved patient outcomes, enhanced quality of life, and reduced strain on resources.


CareMetx

Latest:

What Do Pharmaceutical Manufacturers Actually Want Most from a Hub?

Among a variety of Hub vendors, what specific qualities distinguish differentiated support for drug manufacturers? To help answer this question, CareMetx conducted in-depth interviews and surveys with senior leadership at top manufacturers.



John Wirthlin, Zebra Technologies

Latest:

New Serialization Mandates Inch Closer

Pressure is mounting ahead of looming unit-level serialization required by the Drug Supply Chain Security Act—necessitating a wide scope of collaboration on compliance



Laura Riccio

Latest:

Operating Without a Commercial Blueprint: Empowering the Field for Niche Therapy Launches

How emerging biotech companies can create fruitful partnerships between home office commercial teams and the field force to enable this intelligence gathering, while driving commercial success.


Ramesh Krishnan, Ph.D. and Jacob Maman

Latest:

Evaluating Patient Support Programs: Opportunities and Pitfalls

Assessing the efficacy of patient support programs is the first step to optimizing their resource allocation and program design for maximized patient benefit.


Mahesh Veerina, ParkourSC

Latest:

Key Supply Chain Tech Trends for 2023

Outlining those advances poised to drive increased use of integrated tactical planning (ITP) in helping manufacturers overcome persistent supply chain obstacles.


Ankitkumar C. Patel

Latest:

Technically Speaking: Quality Documentation is One of the Best Ways to Boost Performance

Why well-organized documentation is critical at every stage of the process.


Don Tracy, Associate Editor

Latest:

Hubs East 2025: Adapting to Patient Needs: How Engagement Strategies Are Evolving in Specialty Pharmacy

Jen Butler, chief commercial officer, Pleio, discusses how personalization, connectivity, technology, and proactive support are working to evolve patient engagement strategies.


Liz Cornish

Latest:

The Impact of Serialization Technology: Ensuring Product Integrity and Regulatory Compliance

These advancements continue to act as a key driver in helping to boost the security, efficiency, and innovation of global industries, include pharma.


Dan Cardinal, Melissa McDevitt, Dan Wetherill

Latest:

A Game Changer for Commercial Insights?

Configuration-driven SaaS, powered by modern data management technology, can enable orphan drug manufacturers to form effective commercial strategies


Erica Conroy, CoverMyMeds

Latest:

Specialty access barriers: How technology can help

2020 was a difficult year for many patients, but new data may signal a brighter future ahead


Craig Wilson, Marken

Latest:

Medicine for the Planet: Building a Sustainable Legacy in Pharma Supply Chains

New innovations that are contributing to industry environmental efforts.


Joel Morse

Latest:

How Healthcare Economics Outcomes Evidence Can Pave the Way for Digital Therapeutics

In the face of chronic disease, DTx have the opportunity to provide a lifeline to patients.



Steven Lucio and Jenna Stern

Latest:

Exclusivity Creates Challenges in Price, Access for Long-used Medications

FDA’s Unapproved Drug Initiative (UDI) is a well-intentioned program in its encouragement of formal FDA review for unapproved legacy medications. But it has inadvertently created financial challenges and access issues, write Steven Lucio and Jenna Stern


Ben Jones, The US Oncology Network

Latest:

Health policies high on specialty radar in 2021

The key trends and considerations for specialty providers navigating a changing policy landscape


Nareda Mills

Latest:

Revolutionizing Rare Disease Treatment: Embracing the Patient-Centric Transformation in Pharmaceutical Customer Engagement

Navigating the complex landscape of healthcare coverage can be an intimidating task, especially for patients with rare diseases for which treatments often come with a high price tag.


Anil Shankar, Adria Warren, and Jordan Smiley

Latest:

Critical Year Ahead for the 340B Drug Pricing Program

The courts reversed certain key guidance documents issued by the Health Resources and Services Administration for the 340B Program, which raises uncertainty.


Maria Cipicchio, OptimizeRx

Latest:

Navigating the Biosimilars Marketplace

How to provide effective brand engagement in this rocky yet emerging landscape.


Kostja Paschalidis

Latest:

Future of Personalized Medicine Hinges on Pharma Executives Revolutionizing Business Models

The era of big pharma as product-first companies must end, as services become the larger priority.


Mike Rousselle, OptimizeRx

Latest:

Applying AI Case Studies in Pharma 

How artificial intelligence and real-world data has not just helped predict patient behavior, but has also been successful at the point-of-care for life sciences companies.  


Accreditation Council for Medical Affairs (ACMA)

Latest:

Medical Affairs Role in Shaping Strategy

What the Changing Healthcare Landscape Demands of Future MA Professionals?


Dan Bell

Latest:

Unpacking the High Cost of GLP-1 Drugs

How can industry stakeholders ensure the quality and supply chain security of existing product?


Lauren Biscaldi

Latest:

Illinois Governor Signs Legislation Targeting PBM Retaliation

Illinois Governor JB Pritzker signed into a law a bill prohibiting PBM retaliation against pharmacists who disclose information during government proceedings.


Ross Bjella, DDN

Latest:

Leading in Challenging Times

It has been said that one should never miss an opportunity to make the most of a crisis. The steady stream of headlines announcing staff cuts, delays in drug approvals and a narrowing of R&D focus for pharmaceutical and biotech companies indicate there will be no shortage of opportunities in 2009.


© 2025 MJH Life Sciences

All rights reserved.